Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenabasum in Diffuse Cutaneous Systemic Sclerosis
NCT02465437Phase 2Terminated
- Sponsor
- Corbus Pharmaceuticals Holdings, Inc.
- Start
- Aug 2015
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenabasum in diffuse cutaneous systemic sclerosis (dcSSc), sponsored by Corbus Pharmaceuticals Holdings, Inc.. Started Aug 2015; status: terminated.
02
Drugs
lenabasum
03
Conditions
diffuse cutaneous systemic sclerosis (dcSSc)
Beyond the preview
Go deeper on NCT02465437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02465437.